442 related articles for article (PubMed ID: 25620167)
1. Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises.
Santoni M; Scarpelli M; Mazzucchelli R; Lopez-Beltran A; Cheng L; Cascinu S; Montironi R
J Biol Regul Homeost Agents; 2014; 28(4):555-63. PubMed ID: 25620167
[TBL] [Abstract][Full Text] [Related]
2. PET imaging in prostate cancer: focus on prostate-specific membrane antigen.
Mease RC; Foss CA; Pomper MG
Curr Top Med Chem; 2013; 13(8):951-62. PubMed ID: 23590171
[TBL] [Abstract][Full Text] [Related]
3. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
[TBL] [Abstract][Full Text] [Related]
4. PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status.
Lütje S; Heskamp S; Cornelissen AS; Poeppel TD; van den Broek SA; Rosenbaum-Krumme S; Bockisch A; Gotthardt M; Rijpkema M; Boerman OC
Theranostics; 2015; 5(12):1388-401. PubMed ID: 26681984
[TBL] [Abstract][Full Text] [Related]
5. Advances in prostate-specific membrane antigen PET of prostate cancer.
Bouchelouche K; Choyke PL
Curr Opin Oncol; 2018 May; 30(3):189-196. PubMed ID: 29465429
[TBL] [Abstract][Full Text] [Related]
6. Anti-PSMA
Frigerio B; Morlino S; Luison E; Seregni E; Lorenzoni A; Satta A; Valdagni R; Bogni A; Chiesa C; Mira M; Canevari S; Alessi A; Figini M
J Exp Clin Cancer Res; 2019 Jul; 38(1):326. PubMed ID: 31337429
[TBL] [Abstract][Full Text] [Related]
7. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer.
Ghosh A; Heston WD
J Cell Biochem; 2004 Feb; 91(3):528-39. PubMed ID: 14755683
[TBL] [Abstract][Full Text] [Related]
8. Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness.
Ghosh A; Wang X; Klein E; Heston WD
Cancer Res; 2005 Feb; 65(3):727-31. PubMed ID: 15705868
[TBL] [Abstract][Full Text] [Related]
9. Moderate expression of prostate-specific membrane antigen, a tissue differentiation antigen and folate hydrolase, facilitates prostate carcinogenesis.
Yao V; Parwani A; Maier C; Heston WD; Bacich DJ
Cancer Res; 2008 Nov; 68(21):9070-7. PubMed ID: 18974153
[TBL] [Abstract][Full Text] [Related]
10. Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer.
Ceci F; Castellucci P; Fanti S
Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):7-18. PubMed ID: 29521482
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
[TBL] [Abstract][Full Text] [Related]
12. New aspects of molecular imaging in prostate cancer.
Ceci F; Castellucci P; Cerci JJ; Fanti S
Methods; 2017 Nov; 130():36-41. PubMed ID: 28711565
[TBL] [Abstract][Full Text] [Related]
13. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.
Chatalic KL; Heskamp S; Konijnenberg M; Molkenboer-Kuenen JD; Franssen GM; Clahsen-van Groningen MC; Schottelius M; Wester HJ; van Weerden WM; Boerman OC; de Jong M
Theranostics; 2016; 6(6):849-61. PubMed ID: 27162555
[TBL] [Abstract][Full Text] [Related]
14. Advances in Urologic Imaging: Prostate-Specific Membrane Antigen Ligand PET Imaging.
Hofman MS; Iravani A; Nzenza T; Murphy DG
Urol Clin North Am; 2018 Aug; 45(3):503-524. PubMed ID: 30031469
[TBL] [Abstract][Full Text] [Related]
15. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.
Rowe SP; Gorin MA; Allaf ME; Pienta KJ; Tran PT; Pomper MG; Ross AE; Cho SY
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):223-30. PubMed ID: 27136743
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications.
Sheehan B; Guo C; Neeb A; Paschalis A; Sandhu S; de Bono JS
Eur Urol Focus; 2022 Sep; 8(5):1157-1168. PubMed ID: 34167925
[TBL] [Abstract][Full Text] [Related]
17. Comparison of
Zamboglou C; Drendel V; Jilg CA; Rischke HC; Beck TI; Schultze-Seemann W; Krauss T; Mix M; Schiller F; Wetterauer U; Werner M; Langer M; Bock M; Meyer PT; Grosu AL
Theranostics; 2017; 7(1):228-237. PubMed ID: 28042330
[TBL] [Abstract][Full Text] [Related]
18. A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer.
Ganguly T; Dannoon S; Hopkins MR; Murphy S; Cahaya H; Blecha JE; Jivan S; Drake CR; Barinka C; Jones EF; VanBrocklin HF; Berkman CE
Nucl Med Biol; 2015 Oct; 42(10):780-7. PubMed ID: 26169882
[TBL] [Abstract][Full Text] [Related]
19. Detection of circulating prostate cells during radical prostatectomy by standardized PSMA RT-PCR: association with positive lymph nodes and high malignant grade.
Schmidt B; Anastasiadis AG; Seifert HH; Franke KH; Oya M; Ackermann R
Anticancer Res; 2003; 23(5A):3991-9. PubMed ID: 14666708
[TBL] [Abstract][Full Text] [Related]
20. New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen.
Cimadamore A; Cheng M; Santoni M; Lopez-Beltran A; Battelli N; Massari F; Galosi AB; Scarpelli M; Montironi R
Front Oncol; 2018; 8():653. PubMed ID: 30622933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]